BI-furc-Asian: Boehringer's tiered strategy to get novel drugs to emerging markets
This article was originally published in Scrip
Executive Summary
Professor Dr Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim, believes that as part of an improved pricing strategy across the industry there was a need to develop a tiered pricing system which ensures better access to novel medicines in some emerging markets.